RFK Jr.'s vaccine skepticism creating environment where vaccines harder to develop
RFK Jr.'s vaccine skepticism is undermining vaccine development as manufacturers reconsider U.S. market investment, FDA staff resign, and federal funding for mRNA research was slashed.
Objective Facts
Former CDC Chief Medical Officer Dr. Debra Houry resigned from the agency in protest last summer alongside three other top officials, describing turmoil and concern inside the agency, particularly over the June 9, 2025, removal of experts from a key vaccine advisory panel and Kennedy's refusal to receive briefings on ongoing health crises, stating "Science doesn't change based on who is in office, and so when these things were happening, I knew this was different than before." A challenging public health policy landscape under RFK Jr. has vaccine makers rethinking developing for the U.S. market, with some developers reevaluating investing in late-stage trials, and Moderna CEO Bancel stating the company does not plan to continue investments into new late-stage vaccine trials because of the current environment. RFK Jr. halted 22 mRNA vaccine initiatives through cancellation of contracts with Emory University, Pfizer, and others. Dr. Peter Marks, the FDA's top vaccine expert, resigned in March over concerns about Kennedy's promotion of vaccine misinformation. US-manufactured vaccine sales hit their lowest since the pandemic between 2022 and 2025, with a 75% downward compound annual growth rate attributed partly to declining vaccination rates across the U.S.
Left-Leaning Perspective
Former CDC chief medical officer Dr. Debra Houry told "Face the Nation with Margaret Brennan" that many individuals advising Kennedy had "no medical background, and not only no medical background, no science background, and for many of them, no background in government," and stressed "It's certainly OK to have different perspectives and different expertise, but then you want to make sure that the scientists and the experts are also being heard and part of those decisions, and we weren't." Houry called for an investigation into what's happening at federal health agencies under Kennedy's leadership, accusing him and his allies of political interference and saying Kennedy has caused "irreparable harm" that will be "really difficult to recover from." NBC News reports that many scientists and infectious disease experts swiftly denounced the mRNA funding cuts as "a broadside on an area of research seen as particularly promising," adding that "the cuts add to mounting evidence that Kennedy is pursuing an aggressive anti-vaccine agenda."
Right-Leaning Perspective
The Wall Street Journal's editorial board stated that Kennedy is "already vindicating his critics" after about a month and a half as HHS secretary, expressing concerns that his actions result in a "brain drain" with FDA staff departures, noting that "hopes among Senate Republicans that other Trump appointees like Food and Drug Administration Commissioner Marty Makary would keep Kennedy in check have not panned out," and writing "Mr. Kennedy rightly criticized the Biden Administration's Covid responses for ignoring science, but he won't restore public confidence if he feeds skepticism about vaccines that have saved countless lives." The Journal also noted that Kennedy's "concern about conflicts of interest is especially striking given his own ties to trial lawyers who sue drug companies," as he "helped spearhead litigation against Merck over its HPV vaccine in which he had a 10% financial interest" and "recently agreed to cede his stake to his son who works at the law firm, Wisner Baum, that is suing the company."
Deep Dive
RFK Jr.'s appointment as HHS secretary in February 2025 initiated a systematic dismantling of federal vaccine development capacity that extends beyond rhetoric to concrete policy changes affecting manufacturers' business decisions. The $500 million cancellation of 22 mRNA vaccine research contracts, the withdrawal of funding for Moderna's bird flu vaccine development, and the installation of vaccine skeptics on the CDC's Advisory Committee on Immunization Practices represent coordinated actions that manufacturers are interpreting as regulatory hostility. These actions occur against a backdrop of declining vaccination rates contributing to a 75% downward compound annual growth rate in US-manufactured vaccine sales between 2022 and 2025. The departure of key scientific leaders—FDA vaccine expert Dr. Peter Marks in March and CDC Chief Medical Officer Dr. Debra Houry in August 2025—signals institutional damage beyond policy changes; 80% of CDC center director positions are being served by acting officials due to retirements, firings, or resignations, and career CDC scientists were directed not to speak with career officials or senators. What each perspective gets right and what they leave out: Left-leaning critics accurately identify that federal policy uncertainty and leadership departures directly discourage private sector investment in vaccine development—Moderna CEO's explicit statement about abandoning late-stage trials confirms this mechanism. Their concern about regulatory unpredictability is substantiated by the FDA's initial reject-to-file decision on Moderna's flu vaccine and subsequent reversal, signaling inconsistent regulatory messaging. Right-leaning criticism (particularly from the WSJ) correctly identifies that if Kennedy's true goal is improving health outcomes, his policies work against that objective, noting the contradiction between his stated support for vaccines and the outcomes of his actions. However, far-right enthusiasts describe the policies as "vindication" without engaging substantively with the practical consequence that fewer vaccines get developed and brought to market. The left sometimes overstates the intentionality of destroying the vaccine industry versus the policy's consequences, while the right's more measured tone may understate the systematic nature of the changes. Unresolved questions center on whether manufacturers will relocate development to other countries, how long-term the chilling effect persists once regulatory leadership potentially changes, and whether the policy succeeds in its stated goal of shifting vaccine development to "whole-virus platforms"—a older technology that cannot achieve the speed advantage of mRNA, with mRNA potentially enabling vaccine production for the entire world within a year during a pandemic versus the current 1950s process using embryonated chicken eggs.